Asepticys has secured broad global rights to TriFlect™ technology.
Exclusive global license to broad IP from Tulane University
Global Asepticys IP Estate continues expanding with new R&D discoveries
New chemical entity – not previously used for any pharmaceutical
IP coverage for 2036 and beyond
Key markets protected include the United States, Japan, China, Korea, Australia, Europe, Switzerland, Brazil, Mexico, Canada